GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC

Bulletin Express

05/12

Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.

The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.

The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1191568096"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191568096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191568096?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191568096","market":"us","top_or_hot":-1,"title":"GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-12 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1191568096","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191568096","pubTimestamp":1778586213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物宣布传奇生物向美国SEC提交2026年第一季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.\nThe disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.\nThe Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}